ResearcherMie UniversityNo recent work listed
Yoshinori Azumi
Matched on OpenAlex author ID A5108640139. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 12
2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 4 papers
Papers 7
- The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resec… Co-author DOI 10.1016/j.pan.2019.01.020↗
- Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With S… Co-author DOI 10.1097/mpa.0000000000001227↗
- Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing … Co-author DOI 10.1155/2019/5738614↗
- Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Conditional Factors in Localized Pancreatic Du… Co-author DOI 10.3390/cancers11040514↗
- Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗
- Survival Analysis in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Chemoradiotherapy Followed by Surgery According to the International Consensus o… Co-author DOI 10.3390/cancers10030065↗
- [Open surgical resection for pancreatic cancer]. Co-author PMID 25857000↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shuji Isaji · 7 shared papers, 2015–2019 · strength 0.57
- Paper [Open surgical resection for pancreatic cancer]. PMID 25857000↗
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Yasuhiro Murata · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Aoi Hayasaki · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Shugo Mizuno · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Hiroyuki Kato · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Naohisa Kuriyama · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Hiroyuki Sakurai · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Masashi Kishiwada · 6 shared papers, 2018–2019 · strength 0.47
- Paper The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma under… DOI 10.1016/j.pan.2019.01.020↗
- Paper Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized … DOI 10.1097/mpa.0000000000001227↗
- Paper Prognostic Nutritional Index After Chemoradiotherapy Was the Strongest Prognostic Predictor Among Biological and Condit… DOI 10.3390/cancers11040514↗
- Taijiro TAKEUCHI · 1 shared paper, 2019 · strength 0.08
- Warakorn Jaseanchiun · 1 shared paper, 2019 · strength 0.08
- Ken Ichikawa · 1 shared paper, 2019 · strength 0.08
- Takahiro Ito · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.